About Clay Siegall, Ph.D.
Form D filings for MorphImmune in 2023 list Clay Siegall, Ph.D. as president and chief executive officer, director.
Clay Siegall, Ph.D. first appears on SEC filings in 2023.
Experience
This experience comes from SEC filings. The years are when the filings name Clay Siegall, Ph.D. in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Clay Siegall, Ph.D. works with at each company, as listed on that company's latest Form D.
MorphImmune Inc. · Form D, May 17, 2023
SD
Sunil Singhal, M.D.
Director
PD
Philip Low, Ph.D.
Director
IB
Isaac Barchas
Director
RM
Ronald Martell
Director
FD